Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model

Michael Beeton, Diana Alves, Mark Enright, Andrew Jenkins

Research output: Contribution to journalArticle

24 Citations (Scopus)
144 Downloads (Pure)

Abstract

The Galleria mellonella infection model was used to assess the in vivo efficacy of phage therapy against laboratory and clinical strains of Pseudomonas aeruginosa. In a first series of experiments, Galleria were infected with the laboratory strain P. aeruginosa PAO1 and were treated with varying multiplicity of infection (MOI) of phages either 2h post-infection (treatment) or 2h pre-infection (prevention) via injection into the haemolymph. To address the kinetics of infection, larvae were bled over a period of 24h for quantification of bacteria and phages. Survival rates at 24h when infected with 10 cells/larvae were greater in the prevention versus treatment model (47% vs. 40%, MOI=10; 47% vs. 20%, MOI=1; and 33% vs. 7%, MOI=0.1). This pattern held true when 100 cells/larvae were used (87% vs. 20%, MOI=10; 53% vs. 13%, MOI=1; 67% vs. 7%, MOI=0.1). By 24h post-infection, phages kept bacterial cell numbers in the haemolymph 1000-fold lower than in the non-treated group. In a second series of experiments using clinical strains to further validate the prevention model, phages protected Galleria when infected with both a bacteraemia (0% vs. 85%) and a cystic fibrosis (80% vs. 100%) isolate. Therefore, this study validates the use of G. mellonella as a simple, robust and cost-effective model for initial in vivo examination of P. aeruginosa-targeted phage therapy, which may be applied to other pathogens with similarly low infective doses.
Original languageEnglish
Pages (from-to)196-200
JournalInternational Journal of Antimicrobial Agents
Volume46
Issue number2
DOIs
Publication statusPublished - May 2015

Keywords

  • Galleria mellonella
  • Infection model
  • Phage therapy
  • Pseudomonas aeruginosa

Fingerprint Dive into the research topics of 'Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model'. Together they form a unique fingerprint.

  • Cite this